{"id":8851,"date":"2013-12-27T08:53:46","date_gmt":"2013-12-27T07:53:46","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/?p=8851"},"modified":"2013-12-27T08:53:46","modified_gmt":"2013-12-27T07:53:46","slug":"ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas","status":"publish","type":"post","link":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/","title":{"rendered":"Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas"},"content":{"rendered":"<p>Breslow thickness \u2265 0.75 mm, Clark level \u2265 IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas \u2265 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas &lt; 0.75 mm, SLN metastasis rates are &lt; 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas \u2265 0.75 mm, but further study is needed to define indications for SLNB in melanomas &lt; 0.75 mm.<\/p>\n<p><a title=\"sentinel limphonode metastasis melanoma\" href=\"https:\/\/jco.ascopubs.org\/content\/31\/35\/4387.abstract?sid=4a740832-a617-42d2-b66a-15ef48fb5ab7\">Han D, Zager JS, Shyr Y. Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. Published online before print November 4, 2013, doi: 10.1200\/JCO.2013.50.1114 JCO December 10, 2013 vol. 31 no. 35 4387-4393<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Breslow thickness \u2265 0.75 mm, Clark level \u2265 IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas \u2265 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas &lt; 0.75 mm, SLN metastasis rates are &lt; 5%. By using a 5% metastasis risk threshold, [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":7685,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[209,211],"tags":[328,703,704,705,706],"class_list":["post-8851","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-spotlight","tag-melanoma-en","tag-metastasis","tag-sentinel","tag-sentinel-biopsy","tag-sentinel-limphonode"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas - Il Melanoma<\/title>\n<meta name=\"description\" content=\"Breslow thickness \u2265 0.75 mm, Clark level \u2265 IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas \u2265 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas &lt; 0.75 mm, SLN metastasis rates are &lt; 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas \u2265 0.75 mm, but further study is needed to define indications for SLNB in melanomas &lt; 0.75 mm.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dott.ssa Matilde Angelotti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/\"},\"author\":{\"name\":\"Dott.ssa Matilde Angelotti\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32\"},\"headline\":\"Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas\",\"datePublished\":\"2013-12-27T07:53:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/\"},\"wordCount\":110,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg\",\"keywords\":[\"melanoma\",\"metastasis\",\"sentinel\",\"sentinel biopsy\",\"sentinel limphonode\"],\"articleSection\":[\"News\",\"Spotlight\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/\",\"name\":\"Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas - Il Melanoma\",\"isPartOf\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg\",\"datePublished\":\"2013-12-27T07:53:46+00:00\",\"description\":\"Breslow thickness \u2265 0.75 mm, Clark level \u2265 IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas \u2265 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas &lt; 0.75 mm, SLN metastasis rates are &lt; 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas \u2265 0.75 mm, but further study is needed to define indications for SLNB in melanomas &lt; 0.75 mm.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage\",\"url\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg\",\"contentUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg\",\"width\":800,\"height\":556,\"caption\":\"Melanoma\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#website\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/\",\"name\":\"Il Melanoma\",\"description\":\"la guida alla conoscenza, prevenzione e cura del melanoma\",\"publisher\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#organization\",\"name\":\"Il Melanoma\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png\",\"contentUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png\",\"width\":300,\"height\":29,\"caption\":\"Il Melanoma\"},\"image\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32\",\"name\":\"Dott.ssa Matilde Angelotti\",\"description\":\"Dott.ssa Matilde Angelotti- Medico Chirurgo - Esame dermatoscopico per l\u2019analisi dei nevi\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/author\/nicola-angelotti\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas - Il Melanoma","description":"Breslow thickness \u2265 0.75 mm, Clark level \u2265 IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas \u2265 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas &lt; 0.75 mm, SLN metastasis rates are &lt; 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas \u2265 0.75 mm, but further study is needed to define indications for SLNB in melanomas &lt; 0.75 mm.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/","twitter_misc":{"Written by":"Dott.ssa Matilde Angelotti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#article","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/"},"author":{"name":"Dott.ssa Matilde Angelotti","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32"},"headline":"Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas","datePublished":"2013-12-27T07:53:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/"},"wordCount":110,"commentCount":0,"publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg","keywords":["melanoma","metastasis","sentinel","sentinel biopsy","sentinel limphonode"],"articleSection":["News","Spotlight"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/","url":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/","name":"Ulceration, Breslow thickness and Clark level significantly predicted sentinel lymph node disease in patients with thin melanomas - Il Melanoma","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg","datePublished":"2013-12-27T07:53:46+00:00","description":"Breslow thickness \u2265 0.75 mm, Clark level \u2265 IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas \u2265 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas &lt; 0.75 mm, SLN metastasis rates are &lt; 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas \u2265 0.75 mm, but further study is needed to define indications for SLNB in melanomas &lt; 0.75 mm.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/ulceration-breslow-thickness-clark-level-significantly-predicted-sentinel-lymph-node-disease-patients-thin-melanomas\/#primaryimage","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/12\/Melanoma-pd1.jpg","width":800,"height":556,"caption":"Melanoma"},{"@type":"WebSite","@id":"https:\/\/www.ilmelanoma.com\/en\/#website","url":"https:\/\/www.ilmelanoma.com\/en\/","name":"Il Melanoma","description":"la guida alla conoscenza, prevenzione e cura del melanoma","publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ilmelanoma.com\/en\/#organization","name":"Il Melanoma","url":"https:\/\/www.ilmelanoma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","width":300,"height":29,"caption":"Il Melanoma"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32","name":"Dott.ssa Matilde Angelotti","description":"Dott.ssa Matilde Angelotti- Medico Chirurgo - Esame dermatoscopico per l\u2019analisi dei nevi","url":"https:\/\/www.ilmelanoma.com\/en\/author\/nicola-angelotti\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/8851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=8851"}],"version-history":[{"count":1,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/8851\/revisions"}],"predecessor-version":[{"id":8852,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/8851\/revisions\/8852"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media\/7685"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=8851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/categories?post=8851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/tags?post=8851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}